Zhengyu W. Jiang

Jiang Su Key Laboratory Of Drug Design And Optimization And Department Of Medicinal Chemistry
Nanjing, 210009, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 53 publications

Discovery of a Biased Kelch-like ECH-Associated Protein 1-p62 (Keap1-p62) Protein-Protein Interaction (PPI) Inhibitor for the Management of p62 Aberrant Hepatocellular Carcinoma.

Discovery of a Biased Kelch-like ECH-Associated Protein 1-p62 (Keap1-p62) Protein-Protein Interaction (PPI) Inhibitor for the Management of p62 Aberrant Hepatocellular Carcinoma.

Journal: Journal of medicinal chemistry

Published: May 30, 2026

Harnessing the E3 Ligase KLHL12 for Tumor-Selective Protein Degradation.

Harnessing the E3 Ligase KLHL12 for Tumor-Selective Protein Degradation.

Journal: Angewandte Chemie (International ed. in English)

Published: May 01, 2026

Chemical intervention strategies targeting MYC for cancer therapy.

Chemical intervention strategies targeting MYC for cancer therapy.

Journal: Drug discovery today

Published: March 26, 2026

Scaffold Hopping-Guided Design of Novel PIM-1 Inhibitors with Anticancer Activities.

Scaffold Hopping-Guided Design of Novel PIM-1 Inhibitors with Anticancer Activities.

Journal: Molecules (Basel, Switzerland)

Published: January 30, 2026

From Covalent to Supramolecular: Re-Thinking Lysosome-Targeting Chimeras Through Modular and Tunable Proximity Control.

From Covalent to Supramolecular: Re-Thinking Lysosome-Targeting Chimeras Through Modular and Tunable Proximity Control.

Journal: Chemistry (Weinheim an der Bergstrasse, Germany)

Published: December 27, 2025

Discovery of a Prodrug of Bardoxolone Methyl for the Treatment of Acute Lung Injury.

Discovery of a Prodrug of Bardoxolone Methyl for the Treatment of Acute Lung Injury.

Journal: ChemMedChem

Published: November 21, 2025

Discovery of Phosphorylated Peptidomimetics Targeting Cbl-b SH2 Domain as Orthosteric Cbl-b Inhibitors by an Optimized Fluorescence Polarization Competition Assay.

Discovery of Phosphorylated Peptidomimetics Targeting Cbl-b SH2 Domain as Orthosteric Cbl-b Inhibitors by an Optimized Fluorescence Polarization Competition Assay.

Journal: Journal of medicinal chemistry

Published: August 25, 2025

Reprogramming Macrophage via an Antigen Phagocytosis-Presentation Nanoenhancer for Improved Cancer Immunotherapy.

Reprogramming Macrophage via an Antigen Phagocytosis-Presentation Nanoenhancer for Improved Cancer Immunotherapy.

Journal: ACS nano

Published: August 20, 2025

Discovery of 2-Pyrazolylpyrimidinone Derivatives as New SPOP Inhibitors for Renal Cell Carcinoma Therapy.

Discovery of 2-Pyrazolylpyrimidinone Derivatives as New SPOP Inhibitors for Renal Cell Carcinoma Therapy.

Journal: Journal of medicinal chemistry

Published: July 07, 2025

Rational Design of Novel Quinazolinone-Pyrrolodihydropyrrolone Analogs as PIM/HDAC Dual-Target Inhibitors for the Treatment of Acute Myelocytic Leukemia.

Rational Design of Novel Quinazolinone-Pyrrolodihydropyrrolone Analogs as PIM/HDAC Dual-Target Inhibitors for the Treatment of Acute Myelocytic Leukemia.

Journal: Journal of medicinal chemistry

Published: May 30, 2025

Supramolecular Host-Guest Assemblies for Tunable and Modular Lysosome-Targeting Protein Degradation.

Supramolecular Host-Guest Assemblies for Tunable and Modular Lysosome-Targeting Protein Degradation.

Journal: Angewandte Chemie (International ed. in English)

Published: March 23, 2025

m6A readers: Promising therapeutic targets in cancer treatment.

m6A readers: Promising therapeutic targets in cancer treatment.

Journal: Acta pharmaceutica Sinica. B

Published: March 20, 2025

Showing 1-12 of 53

Last Updated: 09/26/2026